Rodríguez-Morales Alfonso J, López-Medina Eduardo, Arboleda Iván, Cardona-Ospina Jaime A, Castellanos Jaime, Faccini-Martínez Álvaro A, Gallagher Elaine, Hanley Riona, López Pio, Mattar Salim, Pérez Carlos Eduardo, Kastner Randee, Reynales Humberto, Rosso Fernando, Shen Jing, Villamil-Gómez Wilmer E, Fuquen Marcela
Grupo de Investigación Biomedicina, Faculty of Medicine, Fundación Universitaria Autónoma de las Américas-Institución Universitaria Visión de las Américas, Pereira, Risaralda, Colombia.
Master of Clinical Epidemiology and Biostatistics, Universidad Científica del Sur, Lima, Perú.
PLoS Negl Trop Dis. 2024 Dec 12;18(12):e0012718. doi: 10.1371/journal.pntd.0012718. eCollection 2024 Dec.
Dengue is hyperendemic in Colombia. It imposes a substantial economic burden on patients, caregivers, society, and the national health system. We intend to identify and synthesize the evidence regarding the economic burden of dengue in Colombia.
A systematic review (PROSPERO CRD42021257985) of economic studies was performed. A comprehensive search was completed in PubMed, EMBASE, the Cochrane Library, the LILACS, and SciELO databases. Study selection and data extraction was made by two researchers.
160 records were identified. Of these, 14 studies were selected for data extraction. Direct medical cost of dengue is mainly represented by hospitalization (USD 823 to 1,754). The annual aggregated cost is near to USD 159.6 million, with ambulatory care (USD 90.1 million) and fatal cases (USD 30.7 million) representing 75% of the total cost. The aggregate indirect cost (due to loss in income while sick or as a caretaker) was USD 92.8 million. Vaccination seems to reduce the economic cost of dengue.
Dengue financial burden could be challenging for low-income communities as those affected in Colombia. An integrated approach including vector control and the introduction of a vaccine for dengue has the potential to reduce the economic burden of the disease.
登革热在哥伦比亚高度流行。它给患者、护理人员、社会和国家卫生系统带来了巨大的经济负担。我们旨在识别和综合有关哥伦比亚登革热经济负担的证据。
对经济研究进行了系统评价（PROSPERO CRD42021257985）。在PubMed、EMBASE、Cochrane图书馆、LILACS和SciELO数据库中完成了全面检索。由两名研究人员进行研究选择和数据提取。
共识别出160条记录。其中，14项研究被选中进行数据提取。登革热的直接医疗费用主要由住院费用构成（823美元至1754美元）。年度总费用接近1.596亿美元，其中门诊护理（9010万美元）和死亡病例（3070万美元）占总费用的75%。间接费用总计（因患病或作为护理人员而导致的收入损失）为9280万美元。接种疫苗似乎可以降低登革热的经济成本。
登革热的经济负担对于像哥伦比亚受影响的那些低收入社区来说可能具有挑战性。包括病媒控制和引入登革热疫苗在内的综合方法有可能减轻该疾病的经济负担。
